Related Experiment Video
Updated: Jan 26, 2026

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
CD18 inhibits progression of kidney cancer by down-regulating Treg cell levels
1Department of Urology, Dongyang People's Hospital, Dongyang, Zhejiang, China. bdyt0zxc526s@sina.com.
Objective:
Gene mutation is closely related to the occurrence of tumor. Renal cell carcinoma is a malignant tumor, seriously threatening patients' life quality. Regulatory T cells (Treg) play important roles in the development of several cancers. This study aimed to investigate whether CD18 affects renal carcinoma cell proliferation.
Materials And Methods:
Thirty mice with renal cell carcinoma were constructed using gene-engineering mouse with CD18 deficiency, and another 30 normal C57 mice were used as control. Ki67 and micro-vessel density were detected by using immunohistochemistry (IHC) and immunofluorescence, respectively. The expression of CD3, CD4 and CD8 were detected in blood and spleen by quantitative PCR (q-PCR). Flow cytometry was used to detect the changes of Treg cells.
Results:
The expression of Ki67 in C57 was significantly higher than that in CD18-/- mice (p<0.05). IHC results showed that CD31 was also significantly downregulated in CD18-/- group compared to control group (p<0.05). It was found that only high expression of CD4 in mesenteric lymph nodes of CD18-/- was considered as non-tumor-bearing. Flow cytometry results showed that Treg cells were significantly decreased in CD18-/- compared to C57 group (p<0.05).
Conclusions:
CD18-/- down-regulates Treg cells and inhibits the pathogenesis of renal cell carcinoma.
Insights
CD18 deficiency significantly reduces regulatory T cells (Treg) and inhibits renal cell carcinoma progression in mice. This finding suggests CD18 plays a role in kidney cancer development.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Gene mutations are linked to tumor development.
- Renal cell carcinoma (RCC) is a serious cancer.
- Regulatory T cells (Treg) influence cancer progression.
Purpose of the Study:
- To investigate the effect of CD18 on renal cell carcinoma proliferation.
- To explore the role of CD18 in kidney cancer pathogenesis.
Main Methods:
- Utilized CD18-deficient and C57 mice models for renal cell carcinoma.
- Assessed Ki67 proliferation marker and micro-vessel density via IHC and immunofluorescence.
- Quantified CD3, CD4, CD8 expression using q-PCR and Treg cell populations via flow cytometry.
Main Results:
- CD18 deficiency led to significantly lower Ki67 expression and CD31 levels.
- Reduced Treg cell populations were observed in CD18-deficient mice.
- High CD4 expression in lymph nodes indicated a non-tumor-bearing state in CD18-/- mice.
Conclusions:
- CD18 deficiency down-regulates Treg cells.
- CD18 deficiency inhibits the pathogenesis of renal cell carcinoma.
- CD18 is a potential target for kidney cancer therapy.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Feedback Inhibition
Epigenetic Regulation
Positive Regulator Molecules
pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...
Master Transcription Regulators

